Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the …
NL Moore, AR Hanson, E Ebrahimie, TE Hickey… - The Journal of Steroid …, 2020 - Elsevier
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the …
NL Moore, AR Hanson, E Ebrahimie… - The Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the …
NL Moore, AR Hanson, E Ebrahimie… - Journal of Steroid …, 2020 - research.sahmri.org.au
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the …
NL Moore, AR Hanson, E Ebrahimie… - Journal of Steroid …, 2019 - hero.epa.gov
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the …
NL Moore, AR Hanson, E Ebrahimie… - The Journal of Steroid …, 2019 - europepmc.org
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …
ANTI-proliferative transcriptional effects of medroxyprogesterone acetate in Estrogen receptor positive breast cancer cells are predominantly mediated by ThE …
NL Moore, AR Hanson, E Ebrahimie, TE Hickey… - 2019 - digital.library.adelaide.edu.au
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …
ANTI-proliferative transcriptional effects of medroxyprogesterone acetate in Estrogen receptor positive breast cancer cells are predominantly mediated by ThE …
NL Moore, AR Hanson, E Ebrahimie, TE Hickey… - 2019 - hekyll.services.adelaide.edu.au
Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …
use for various hormonal conditions in women since the 1960s. Although developed as a …